This novel mechanism of GAS5 suppressing stomach carcinogenesis via the YBX1/p21 pathway serves as a potential target for the development of lncRNA-based therapeutics for the treatment of stomach cancer. The gene discussed is YBX1; the disease is gastric cancer.